Why the study?
Molecular insights into calcific aortic valve disease initiation and progression are limited and pharmacotherapies remain unavailable despite devastating clinical sequelae.
Key points are not available for this paper at this time.
Design
Review
Limited molecular insights leave calcific aortic valve disease without pharmacotherapies; leaves open mechanistic research to identify targets.
Despite devastating clinical sequelae of calcific aortic valve disease that range from left ventricular remodeling to arrhythmias, heart failure, and early death, the molecular insights into disease initiation and progression are limited and pharmacotherapies remain unavailable. The pathobiology of calcific aortic valve disease is complex and comprehensive studies are challenging valvular calcification is heterogeneous and occurs preferentially on the aortic surface, along a fibrocalcific spectrum. Here, we review efforts to study (epi-)genomic, transcriptomic, proteomic, and metabolomic aspects of aortic valve calcification in combination with network medicine-/systems biology-based strategies to integrate multilayered omics datasets and prioritize druggable targets for experimental validation studies. Ultimately, such holistic approach efforts may open therapeutic avenues that go beyond invasive and costly valve replacement therapy.
No takes yet. Share an insight, caveat, or question.
Blaser et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: